Innovative Synthetic Molecule Design Engineer

BioSpace; Indianapolis (IN); On-site; USD 66,000 - 172,000; Full time

Benefits offered by this job

Company bonus

401(k) plan

Health insurance

Vacation benefits

Pension

Job summary

Lilly, headquartered in Indianapolis, Indiana, seeks a ChemE for synthetic molecule design and process development. The role focuses on developing and optimizing crystallization processes, PAT integration, and scale-up for drug substances and products.

You will collaborate with chemists, engineers, and formulation scientists to deliver robust, well-characterized processes supporting clinical trials and commercialization. Travel 0–10% is possible, with a strong emphasis on safety and quality.

Qualifications

• B.S. or M.S. in chemical engineering or closely related field.
• Authorized to work in the United States on a full-time basis; Lilly does not sponsor visas.

Responsibilities

• Generate process design and unit operation knowledge for small molecules.
• Ensure successful scale-up of processes.
• Design and execute laboratory experiments for crystallization process design and optimization.
• Develop drug substance processes and crystallization to meet properties and purity requirements.
• Leverage PAT and analytical technology for robust crystallization processes.
• Characterize reaction kinetics and process separations with modeling.

Skills

Synthetic organic chemistry

Crystallization design

PAT and analytical techniques

Problem solving

Communication skills

Project prioritization

Education

B.S. or M.S. in chemical engineering

Tools

XRPD

DSC

TGA

FBRM

Image analysis

Job description

Lilly, headquartered in Indianapolis, Indiana, seeks a ChemE for synthetic molecule design and process development. The role focuses on developing and optimizing crystallization processes, PAT integration, and scale-up for drug substances and products.

You will collaborate with chemists, engineers, and formulation scientists to deliver robust, well-characterized processes supporting clinical trials and commercialization. Travel 0–10% is possible, with a strong emphasis on safety and quality.